Patents by Inventor Maxim M. Bespalov

Maxim M. Bespalov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Neurturin molecules
    Patent number: 9469679
    Abstract: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: October 18, 2016
    Assignee: NTF Therapeutics, Inc.
    Inventors: Pia Runeberg-Roos, Maxim M. Bespalov, Richard Penn, Mart Saarma
  • Neurturin molecules
    Patent number: 9127083
    Abstract: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: September 8, 2015
    Assignee: NTF Therapeutics, Inc.
    Inventors: Pia Runeberg-Roos, Maxim M. Bespalov, Richard Penn, Mart Saarma
  • NEURTURIN MOLECULES
    Publication number: 20150202263
    Abstract: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.
    Type: Application
    Filed: August 26, 2014
    Publication date: July 23, 2015
    Inventors: Pia Runeberg-Roos, Maxim M. Bespalov, Richard Penn, Mart Saarma
  • NEURTURIN MOLECULES
    Publication number: 20150141329
    Abstract: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.
    Type: Application
    Filed: March 18, 2013
    Publication date: May 21, 2015
    Inventors: Pia Runeberg-Roos, Maxim M. Bespalov, Richard Penn, Mart Saarma
  • NEURTURIN MOLECULES
    Publication number: 20130274186
    Abstract: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.
    Type: Application
    Filed: March 18, 2013
    Publication date: October 17, 2013
    Inventors: Pia Runeberg-Roos, Maxim M. Bespalov, Richard Penn, Mart Saarma
  • Neurturin molecules
    Patent number: 8445432
    Abstract: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: May 21, 2013
    Assignees: NTF Therapeutics Inc, University of Helsinki
    Inventors: Richard Penn, Pia Runeberg-Roos, Maxim M. Bespalov, Mart Saarma
  • NEURTURIN MOLECULES
    Publication number: 20110312883
    Abstract: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.
    Type: Application
    Filed: November 15, 2010
    Publication date: December 22, 2011
    Applicants: CNS THERAPEUTICS, INC.
    Inventors: Pia Runeberg-Roos, Maxim M. Bespalov, Richard Penn, Mart Saarma